Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419536 · ClinicalTrials.gov registry record · Phase 1
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT00419536 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 108 participants.
The verdict
NCT00419536, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419536
The ClinicalTrials.gov registry entry for NCT00419536 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT00419536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419536 about?
NCT00419536 is a clinical study titled "Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone". This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.
What is the current status of trial NCT00419536?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00419536?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00419536?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.